| API | |||
| NO. | Product name | USE | CAS NO. |
| 1 | Rivaroxaban | Anticoagulant | 366789-02-8 |
| 2 | Apixaban | Anticoagulant | 503612-47-3 |
| 3 | Empagliflozin | Type 2 diabetes mellitus | 864070-44-0 |
| 4 | Dapagliflozin Propanediol monohydrate | Type 2 diabetes mellitus | 960404-48-2 |
| 5 | Canagliflozin Hemihydrate | Type 2 diabetes mellitus | 928672-86-0 |
| 6 | Trelagliptin Succinate | Type 2 diabetes mellitus | 1029877-94-8 |
| 7 | Alogliptin Benzoate | Type 2 diabetes mellitus | 850649-62-6 |
| 8 | Linagliptin | Type 2 diabetes mellitus | 668270-12-0 |
| 9 | Regorafenib Monohydrate | Anti-cancer | 1019206-88-2 |
| 10 | Relugolix | Anti-cancer | 737789-87-6 |
| 11 | Lapatinib Ditosylate | Anti-cancer | 388082-78-8 |
| 12 | Palbociclib | Anti-cancer | 571190-30-2 |
| 13 | Nintedanib Esylate | Anti-cancer | 656247-18-6 |
| 14 | Axitinib | Anti-cancer | 319460-85-0 |
| 15 | Pazopanib Hydrochloride | Anti-cancer | 635702-64-6 |
| 16 | Cabozantinib Malate | Anti-cancer | 1140909-48-3 |
| 17 | Sunitinib Malate | Anti-cancer | 341031-54-7 |
| 18 | Vandetanib | Anti-cancer | 443913-73-3 |
| 19 | Lenvatinib Mesylate | Anti-cancer | 857890-39-2 |
| 20 | Sorafenib Tosylate | Anti-cancer | 475207-59-1 |
| 21 | Ceritinib | Anti-cancer | 1032900-25-6 |
| 22 | Crizotinib | Anti-cancer | 877399-52-5 |
| 23 | Osimertinib Mesylate | Anti-cancer | 1421373-66-1 |
| 24 | Afatinib Dimaleate | Anti-cancer | 850140-73-7 |
| 25 | Erlotinib Hydrochloride | Anti-cancer | 183319-69-9 |
| 26 | Ibrutinib | Anti-cancer | 936563-96-1 |
| 27 | Nilotinib Hydrochloride Monohydrate | Anti-cancer | 923288-90-8 |
| 28 | Dasatinib Monohydrate | Anti-cancer | 863127-77-9 |
| 29 | Imatinib Mesylate | Anti-cancer | 220127-57-1 |
Disclaimer:Products are only available to countries where there is no valid patent protection. Products still covered by patents rights are available exclusively for experimental or registration purpose pursuant to national applicable law, and shall be sold in strict accordance with the laws of the People's Republic of China and the laws of the Buyer's country. All products are not for human use. Buyer is obligated for evaluation of the patent situation in its domestic market and shall be held liable for uses which do not fall within the scope of the experimental or registration use exception and are not permitted by national applicable law.